# A Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis

> **NCT06092762** · PHASE2 · COMPLETED · sponsor: **Akeso** · enrollment: 180 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** AK120

## Key facts

- **NCT ID:** NCT06092762
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-06
- **Primary completion:** 2024-11-13
- **Final completion:** 2024-11-13
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2024-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06092762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06092762, "A Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06092762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*